Select Page

A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.

Shift Health conducted targeted secondary research to gather evidence that substantiates the case for public sector investment in programs, policies and infrastructure that would enable access to Chimeric Antigen Receptor (CAR) T-cell therapies. Our team worked with different functions of the client team—including government relations, medical, commercial and communications—to translate the evidence into a set of messages backed by a curated catalogue of information sources.

Our client is armed with a compelling, evidence-based story to support dialogue with the policymakers that will set the stage for a new era of cellular-based immunotherapies.